Header Logo

Connection

Alan Go to Thromboembolism

Back to Details
This is a "connection" page, showing publications Alan Go has written about Thromboembolism.
Alan Go
Connection Strength
2.495
Thromboembolism
  1. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21; 2(3):e000250.
    View in: PubMed
    Score: 0.450
  2. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010 Oct; 138(4):1020; author reply 1020-1.
    View in: PubMed
    Score: 0.373
  3. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.352
  4. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.334
  5. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
    View in: PubMed
    Score: 0.232
  6. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015 Jan 01; 115(1):40-6.
    View in: PubMed
    Score: 0.123
  7. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014 Aug 15; 114(4):583-6.
    View in: PubMed
    Score: 0.120
  8. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 01; 151(5):297-305.
    View in: PubMed
    Score: 0.087
  9. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.085
  10. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26; 51(8):810-5.
    View in: PubMed
    Score: 0.078
  11. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.077
  12. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.066
  13. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.058
  14. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.036
  15. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):624-31.
    View in: PubMed
    Score: 0.023

© 2024 Kaiser Permanente